banner

Target Safety Assessment & Target Intelligence

Target Safety Assessment is essential for the success of your toxicology studies. Understanding your target early in drug development will ensure that you can de-risk your target, reduce the cost of your of toxicology studies and reduce the time spent in the preclinical stage.

At Metisox we can provide precision insights for your target(s) and you will receive a complete Target Profile. This includes target safety assessment, target intelligence, mechanistic driven drug discovery and identification of potential safety biomarker candidates. Our proprietary AI tools, machine learning and clinical data sources can search unexplored areas of biology to identify potential adverse effects, new targets for your pipeline as well as target repurposing options.

Metisox offers these as a complete package or as separate modules depending on your requirements and stage of your project.

Join our Webinar: Mini-Target Safety Assessment (Mini-TSA)

9th December 2021 @5pm (GMT) / 12pm (EST) / 9am (PST)

In this webinar you will learn about:

  • Challenges in target safety profiling and target safety related drug attrition
  • Advantages of utilizing a mini-TSA early in your program
  • Overview of a mini-Target Safety Assessment Report

Recently, we launched our new rapid and concise mini-TSA report that delivers known on-target toxicities and summarizes potential safety risks associated with modulation of your target within five days. Join our webinar and learn how these reports can be applied in your drug development process to de-risk your programs.

Target Safety Assessment Pipeline

Your TSA report will include the biology of target family, target function and involvement in human and animal diseases. The data  is sourced from multiple types of data sources including several publicly available databases combined together with our proprietary SysWiz database. Metisox’s SysWiz database is utilised to extract multiomics intelligence; including mRNA and protein expression profiles, related proteins and intra- and inter- species variation.

Metisox has delivered TSA reports for targets from over 75% of all druggable families and looking forward to completing the whole family set with your target(s).

Your Target
Therapeutic indication & biological activity

Over 10 proprietary data sources
Over 30 public data sources

Arrow_connector_5

Datamining
In silico analysis

Biological network & pathway databases

Clinical trials & adverse effects databases

Literature text-mining
Manual & automated curation

Arrow_connector_4

Target analysis
Biological function & multiomics expression
Off-targets, isoforms & homologues
Genetic phenotype of animal and human
Pharmacological & ligand insights
Defined structural features

Cellular & tissue network analysis
Direct & indirect pathway effects of target modulation via protein-protein interactions and associated pathways

ArrowLong

Toxicological Evaluation
Critical adverse effects observed in both preclinical studies and clinical trials

Arrow_connector_6b
Arrow_connector_7b

Target patient population

Toxicity profile & risk ranking
Adverse effects ranked based upon:
Severity
Observed frequency
Evidence
Relevance for patient population

“Outsourcing our Target Safety Assessment Reports to Metisox, for the past 5 years, has helped speed up our toxicology investigations as well as provide insightful mitigation plans that we were unable to deduce from our internal resources”
– Study Director, Toxicology

Arrow_connector_8b

Safety biomarker candidates

Risk Mitigation Plan

Target repurposing options

Target Safety Assessment Reports (TSA Reports)

Metisox combines multiple data sources to deliver concise knowledge driven target safety assessment reports providing an intelligent safety profile of your target. The key output is a Risk Mitigation Plan that provides insights on your target and options to mitigate toxicology risks moving forward. This will include extensive knowledge for making informed decisions on your targets, ranking targets, de-risking strategies and/or designing investigative studies.

We offer three types of TSAs:

  • Mini-TSA Report (Turnaround <5 days)
    Provides insights rapidly for multiple targets following a screen
    Useful for very early preclinical studies when there is limited data available
  • Standard TSA Report (Turnaround <20 days)
    Provides detailed insights for your lead target
    Actionable summary of safety concerns included in executive summary
  • Novel TSA Reports (Turnaround 5 – 20 days)
    Utilises Metisox’s Precision Insights SysWiz database for predicting toxicology for novel targets
    Deeper data mine compare to a Mini-TSA

Bulk discount offer – To learn more about our TSA Reports and/or request information on bulk discount options, please provide your details below:

Are you looking to increase the efficiency and knowledge base of your internal TSA Report writing?

SysWiz Database Subscription

Access to Metisox’s proprietary SysWiz database
Training sessions provided as standard
Individual(s) license or site-wide license available
Utilise cutting edge artificial intelligence tools
Bespoke database modules available upon request
End of year discounts until Dec 31 201
Click here for more information

Precision Insights 2022 Software

Early Access to Metisox’s proprietary Precision Insights Software
Full integration into your bioinformatics pipeline
Bespoke development of artificial intelligence tools
Multiomics data platform
Combine analysis of historical and new data sets
Discounted Pricing available until Dec 31st 2021
Click here for more information